Gynecologic cancer intergroup (GCIG) consensus review for ovarian sex cord stromal tumors

Isabelle Ray-Coquard, Jubilee Brown, Philipp Harter, Diane M. Provencher, Peter C. Fong, Johanna Maenpaa, Jonathan A. Ledermann, Gunter Emons, Dominique Berton Rigaud, Rosalind M. Glasspool, Delia Mezzanzanica, Nicoletta Colombo

Research output: Contribution to journalReview article

Abstract

Sex cord stromal tumors (SCST) are rare cancers of the ovarian area in adults. They constitute a heterogeneous group of tumors that develop from the sex cords and the ovarian stroma. These tumors are detected typically at an early stage, and they may recur as late as 30 years after the initial treatment. Because 70% of the patients present with stage I tumors, surgery represents the most important therapeutic arm. There are no data to support any kind of postoperative adjuvant treatment for patients with stage IA or IB SCSTs, given the indolent nature of these neoplasms and the overall good prognosis. The long natural history of the disease may lead to repeated surgical procedure should a relapse occurs. Platinum-based chemotherapy is currently used for patients with advanced stage SCSTs or recurrent disease, with an overall response rate of 63% to 80%. The indolent nature of SCSTs with the tendency for late recurrence requires long-term follow-up.

Original languageEnglish
Pages (from-to)S42-S47
JournalInternational Journal of Gynecological Cancer
Volume24
Issue number9
DOIs
Publication statusPublished - Nov 1 2014

Keywords

  • First-line treatment
  • Metastatic disease
  • Molecular analysis
  • Rare tumor
  • Sex cord stromal tumors

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynaecology

Fingerprint Dive into the research topics of 'Gynecologic cancer intergroup (GCIG) consensus review for ovarian sex cord stromal tumors'. Together they form a unique fingerprint.

Cite this